CA-TREASURE-DATA
8.10.2020 14:02:14 CEST | Business Wire | Press release
Treasure Data ™ today unveiled its Global Partner Program , offering agencies, consultancies, technology service providers, independent software vendors (ISVs) and data specialists new certifications, training, and technical, marketing and sales support for the Company’s market-leading Customer Data Platform (CDP). The program will be launching with 20 strategically selected partners and is set to grow as we continue to expand our customer base in all territories.
“Enterprises are turning to trusted partners in their respective industries to accelerate customer-centric digital transformation and solve complex data, scale and other obstacles that hinder exceptional brand experiences,” said Stephen Lee, Vice President of Strategy and Business Development, Treasure Data. “Treasure Data’s Global Partner Program helps trusted enterprise partners expand their CDP technical acumen and experience to grow their market and revenue opportunities.”
Certified Partners help customers throughout their entire CDP deployment journey. For agencies, and consultancies, the program offers three tiers—bronze, silver and gold—with level-specific commitments for online training, joint marketing, market development funds (MDF), discounts, and technical and sales support. In addition to access to Treasure Data’s CDP Academy training, partners may also receive additional certified sales and technical training matched to key roles ranging from sales and marketing operations to data architects and scientists. The program is also open to select Treasure Data technology partners.
“Acxiom and its partners strive to drive transformational change for clients through strategic partnerships and we’re excited to be working with such a powerful tool as the Treasure Data CDP,” says Mike Menzer, President, Acxiom International. “Customer Data Platforms are creating a lot of growth right now and we see the Acxiom and Treasure Data combination as a key solution to driving value for our clients.”
“CDPs like Treasure Data are playing an increasingly important role in helping marketers better understand who their customers are,” says Jayne Babine, Executive Vice President, Partnerships and Sales at MightyHive. “As one of the leading full-service global marketing services firms, MightyHive is thrilled to be partnering with Treasure Data to make our clients more successful around data marketing strategy and execution.”
Treasure Data’s CDP unifies and unlocks the full potential of customer data. It captures all online and offline customer interactions as they happen, helping companies to understand all brand interactions with the precise detail needed to engage customers at the right time in the right place. Trusted by more than 400 organizations worldwide, Treasure Data provides an enterprise-scale, independent solution that lets partners work with any existing technology stack and gives them the flexibility to ingest all types of data. This makes it easy to integrate the Treasure Data CDP with partner offerings and preferred solutions stacks to accelerate the delivery of outstanding, personalized data-driven brand experiences.
Partners included in Treasure Data’s Global Partner Program: Accenture, Acxiom, MightyHive in the Gold Tier. Allant, BitBang, Brain+Trust Partners, Merkle (Isobar, Sokrati) Search Discovery, SilverBullet in the Silver Tier. AdGlobal360, Ansira, Exostatic, Gravitai, Green Lyzard, HGS Digital, Hero Digital, Hexagon Data, Keyrus, Verticurl in the Bronze Tier. For more information on our partner program, please visit https://www.treasuredata.com/partnerships/
About Treasure Data
Treasure Data Customer Data Platform (CDP) empowers enterprises by delivering rich insights that drive outstanding customer experiences. Built on a strong data management foundation, our CDP enables brands to securely unify customer data across silos at scale so they can better identify, engage and acquire customers. The highly configurable platform boasts a comprehensive connector network that evolves with your existing technology stack to future-proof all customer data initiatives. Treasure Data has more than 400 customers including Fortune 500 and Global 2000 enterprises, and is a wholly-owned subsidiary of Arm Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom